Multi-center randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent/progressive glioblastoma by Brown, N, McBain, C, Nash, S, Hopkins, K, Sanghera, P, Saran, F, Phillips, M, Dungey, F, Clifton-Hadley, L, Wanek, K, Krell, D, Jeffries, S, Khan, I, Smith, P, Mulholland, P

UK stereotactic ablative radiotherapy trials normal tissue dose constraints tolerance consensus by Hanna, G, Patel, R, Aitken, K, Jain, S, Franks, K, Van As, N, Tree, A, Harrow, S, Eaton, D, McDonald, F, Ahmed, M, Saran, F, Webster, G, Khoo, V, Landau, D, Hawkins, M

UK consensus on normal tissue dose constraints for stereotactic radiotherapy by Hanna, G, Murray, L, Patel, R, Jain, S, Aitken, K, Franks, K, van As, N, Tree, A, Hatfield, P, Harrow, S, McDonald, F, Ahmed, M, Saran, F, Webster, G, Khoo, V, Landau, D, Eaton, D, Hawkins, M